Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Patient-reported outcomes with the use of elranatamab in the MagnetisMM-3 trial

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into patient-reported outcomes (PROs) with the use of elranatamab in relapsed/refractory (R/R) multiple myeloma in patients enrolled in the MagnetisMM-3 trial (NCT04649359). Prof. Mohty further emphasizes the importance of including PRO measurements in clinical trials. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.